|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the EYE 10-K filed Mar 14, 2006. blink rewetter solutions, with further
advancements currently in development. We are also working to develop
over-the-counter artificial tear products.
We plan to supplement our research and development activities with a commitment to identifying and obtaining new technologies through in-licensing, technological collaborations and joint ventures, including the establishment of research relationships with academic institutions and individual researchers.
We spent approximately $61.6 million in 2005, $45.6 million in 2004 and $37.4 million in 2003 on research and development. Total research and development expense in 2005 was $552.4 million, including a non-cash in-process research and development charge of $490.8 million, and in 2004 was $73.7 million, including a non-cash in-process research and development charge of $28.1 million. Research and development spending represented 6.7%, 6.1%, and 6.2% of total net sales in 2005, 2004, and 2003, respectively. We believe that the continuing introduction of new products supplied by our research and development efforts and in-licensing opportunities are critical to our success. There are, however, inherent uncertainties associated with the
7
research and development efforts and the regulatory process and we cannot assure you that any of our research projects will result in new products that we can commercialize.
|
| |||||||
